Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ALL PATIENTS ENROLLED AND TREATED ACROSS ORIGINAL AND FDA-CLEARED EXPANSION COHORTS POSITIVE SAFETY AND EARLY EFFICACY SIGNALS CONTINUE TO SUPPORT LATE-STAGE DEVELOPMENT PLANNING FOR OLASTROCEL IN CHRONIC LOWER BACK PAIN WITH ENROLLMENT AND TREATMENT COMPLETED, ADAPT-RELATED CLINICAL EXECUTION EXPENSES ARE EXPECTED TO DECREASE AS THE PROGRAM TRANSITIONS INTO FOLLOW-UP, DATA MATURATION AND REGULATORY PLANNING COMPANY BELIEVES REDUCED ENROLLMENT- AND TREATMENT-RELATED EXPENDITURES SHOULD HELP PRESERVE CAPITAL, EXTEND OPERATING RUNWAY AND SUPPORT CONTINUED PHASE 3 PREPARATION WITHOUT THE IMMEDIATE NEED FOR ADDITIONAL FUNDRAISING COMPANY REMAINS FULLY ENGAGED IN PATIENT FOLLOW-UP, DATA COLLECTION, RMAT EVALUATION AND PREPARATION FOR PHASE 3 DISCUSSIONS WITH FDA FOR A BROADER CHRONIC LOWER BACK PAIN POPULATION OLASTROCEL POSITIONED AS A POTENTIAL NON-SURGICAL, NON-OPIOID REGENERATIVE THERAPY FOR A LARGE UNDERSERVED MARKET PHOENIX, AUG. 20, 2026 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING REGENERATIVE MEDICINE SOLUTIONS, TODAY ANNOUNCED THAT ALL PATIENTS HAVE NOW BEEN ENROLLED AND TREATED ACROSS THE COMPANY'S ENTIRE FDA-CLEARED ADAPT CLINICAL TRIAL EVALUATING CELZ-201 / OLASTROCEL, INCLUDING THE ORIGINAL STUDY COHORTS AND THE FDA-CLEARED OPIOID EXPANSION COHORT. CELZ-201, ALSO KNOWN AS OLASTROCEL, IS THE COMPANY'S PROPRIETARY PERINATAL TISSUE-DERIVED, ALLOGENEIC REGENERATIVE CELL THERAPY CANDIDATE BEING EVALUATED FOR CHRONIC LOWER BACK PAIN ASSOCIATED WITH DEGENERATIVE DISC DISEASE.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS SUCCESSFULLY COMPLETES ENROLLMENT AND TREATMENT ACROSS ENTIRE FDA-CLEARED ADAPT TRIAL, INCLUDING OPIOID COHORT, ADVANCING CELZ-201 / OLASTROCEL TOWARD RMAT EVALUATION AND PHASE 3 PLANNING

NEWLY ALLOWED PATENT PROTECTS CELL-FREE MYELOCELZ EXOSOME TECHNOLOGY DESIGNED TO SUPPRESS AUTOIMMUNE DESTRUCTION OF INSULIN-PRODUCING CELLS, REINFORCING CREATIVE MEDICAL'S MULTI-PROGRAM DIABETES STRATEGY NEWLY ALLOWED PATENT PROTECTS CELL-FREE MYELOCELZ EXOSOME TECHNOLOGY DESIGNED TO SUPPRESS AUTOIMMUNE DESTRUCTION OF INSULIN-PRODUCING CELLS, REINFORCING CREATIVE MEDICAL'S MULTI-PROGRAM DIABETES STRATEGY

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT COVERING EXOSOME-BASED IMMUNOTHERAPY FOR TYPE 1 DIABETES, DEEPENING IP PROTECTION ACROSS ITS MYELOCELZ, CELZ-101 AND CELZ-201 DIABETES PLATFORMS

HIGHLIGHTS SIGNIFICANT CLINICAL, REGULATORY, AND STRATEGIC PROGRESS, SUPPORTED BY A DISCIPLINED CAPITAL ALLOCATION STRATEGY HIGHLIGHTS SIGNIFICANT CLINICAL, REGULATORY, AND STRATEGIC PROGRESS, SUPPORTED BY A DISCIPLINED CAPITAL ALLOCATION STRATEGY

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ISSUES MID-YEAR UPDATE

PHOENIX, JUNE 30, 2026 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., (NASDAQ: CELZ) (THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO THE ADVANCEMENT OF REGENERATIVE THERAPEUTICS IN THE FIELDS OF IMMUNOTHERAPY, ENDOCRINOLOGY, UROLOGY, NEUROLOGY AND ORTHOPEDIC, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AGREEMENTS WITH CERTAIN HOLDERS OF ITS EXISTING WARRANTS FOR THE IMMEDIATE EXERCISE OF OUTSTANDING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 2,790,340 SHARES OF COMMON STOCK OF THE COMPANY ORIGINALLY ISSUED IN OCTOBER 2025, AT A REDUCED EXERCISE PRICE OF $1.60 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT ON FORM S-3 (FILE NO. 333-291713). THE AGGREGATE GROSS PROCEEDS FROM THE EXERCISE OF THE EXISTING WARRANTS IS EXPECTED TO TOTAL APPROXIMATELY $4.5 MILLION, BEFORE DEDUCTING FINANCIAL ADVISORY FEES. ROTH CAPITAL PARTNERS IS ACTING AS THE COMPANY'S FINANCIAL ADVISOR FOR THIS TRANSACTION. IN CONSIDERATION FOR THE IMMEDIATE EXERCISE OF THE EXISTING WARRANTS FOR CASH, THE COMPANY WILL ISSUE NEW UNREGISTERED WARRANTS TO PURCHASE SHARES OF COMMON STOCK. THE NEW WARRANTS WILL BE EXERCISABLE FOR AN AGGREGATE OF UP TO 5,580,680 SHARES OF COMMON STOCK, AT AN EXERCISE PRICE OF $1.60 PER SHARE UPON THE RECEIPT OF SHAREHOLDER APPROVAL FOR A TERM OF FIVE YEARS FROM THE INITIAL EXERCISE DATE. THE TRANSACTION IS EXPECTED TO CLOSE ON JUNE 30, 2026. THE COMPANY INTENDS TO USE THE NET PROCEEDS FROM THE OFFERING FOR WORKING CAPITAL AND GENERAL CORPORATE PURPOSES. THE NEW WARRANTS DESCRIBED ABOVE WERE OFFERED IN A PRIVATE PLACEMENT PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE 1933 ACT) AND, ALONG WITH THE SHARES OF COMMON STOCK ISSUABLE UPON THEIR EXERCISE, HAVE NOT BEEN REGISTERED UNDER THE 1933 ACT, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION WITH THE SECURITIES AND E

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES AGREEMENTS FOR EXERCISE OF WARRANTS FOR $4.5 MILLION GROSS PROCEEDS

PHOENIX, JUNE 22, 2026 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) ("CREATIVE MEDICAL" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING REGENERATIVE MEDICINE SOLUTIONS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS CLEARED AN EXPANSION OF THE COMPANY'S FDA-CLEARED ADAPT CLINICAL TRIAL EVALUATING CELZ-201 (OLASTROCEL) FOR CHRONIC LOWER BACK PAIN ASSOCIATED WITH DEGENERATIVE DISC DISEASE.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS EXPANDS ADAPT TRIAL UNDER NEW FDA CLEARANCE AND RAPIDLY ADVANCES TOWARD PHASE 3 PLANNING FOR OLASTROCEL IN CHRONIC LOWER BACK PAIN

THE REGULATORY APPROVED CELZ-BIODEFENSE PLATFORM IS DESIGNED TO SCALE TO AT LEAST 1,000 VETERANS THROUGH AI-ENABLED MOBILE-APP DATA COLLECTION AND FIELD-CAPABLE LOGISTICS

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. ADVANCES PROJECT PHOENIX INTO NATIONWIDE AI DRIVEN VIRTUAL DATA COLLECTION PHASE FOR U.S. VETERANS EXPOSED TO BURN PITS AND TOXIC HAZARDS

ULTRASOME DEMONSTRATES STRONG CLINICAL SIGNAL WHILE LEVERAGING GMP-PRODUCED CELZ-201 (OLASTROCEL) TO TARGET LARGE, UNDERSERVED OSTEOARTHRITIS MARKET

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. REPORTS BREAKTHROUGH 93% RESPONSE RATE IN ULTRASOME KNEE OSTEOARTHRITIS PROGRAM, EXPANDING CELZ-201 PLATFORM INTO SCALABLE CELL-FREE REGENERATIVE THERAPIES

DATA SHOW STRONG FUNCTIONAL AND PAIN IMPROVEMENTS SUPPORTED BY EXCELLENT SAFETY PROFILE DATA SHOW STRONG FUNCTIONAL AND PAIN IMPROVEMENTS SUPPORTED BY EXCELLENT SAFETY PROFILE

CREATIVE MEDICAL TECHNOLOGY HOLDINGS REACHES MAJOR CLINICAL INFLECTION POINT WITH POSITIVE INTERIM DATA FROM ADAPT TRIAL AND CELZ-201 (OLASTROCEL) IN THE TREATMENT OF CHRONIC LOWER BACK PAIN

PHOENIX, JAN. 06, 2026 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING REGENERATIVE MEDICINE AND AI-ENABLED BIODEFENSE SOLUTIONS, TODAY ANNOUNCED THAT ITS BIODEFENSE INC. BURN PIT INITIATIVE HAS RECEIVED REGULATORY APPROVAL TO PROCEED, MARKING A SIGNIFICANT MILESTONE IN THE COMPANY'S MISSION TO ADDRESS THE LONG-TERM HEALTH CONSEQUENCES OF TOXIC BURN PIT EXPOSURE AMONG U.S. MILITARY VETERANS.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS RECEIVES REGULATORY APPROVAL FOR BIODEFENSE BURN PIT INITIATIVE

COMPLETION OF ENROLLMENT POSITIONS CELZ FOR NEAR-TERM DATA CATALYSTS AND ACCELERATES PATH TOWARD COMMERCIALIZATION OF A TRANSFORMATIVE, NON-OPIOID THERAPY FOR CHRONIC LOWER BACK PAIN COMPLETION OF ENROLLMENT POSITIONS CELZ FOR NEAR-TERM DATA CATALYSTS AND ACCELERATES PATH TOWARD COMMERCIALIZATION OF A TRANSFORMATIVE, NON-OPIOID THERAPY FOR CHRONIC LOWER BACK PAIN

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. COMPLETES ENROLLMENT IN FDA-CLEARED ADAPT TRIAL FOR CELZ-201-OLASTROCEL, MARKING MAJOR CLINICAL INFLECTION POINT

Creative Medical Technology Holdings, Inc.

CELZ

Price

Financial Reports

No items found.

Press Releases

Creative Medical Technology Holdings, Inc.

CELZ.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CELZ